MO34-3 The efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy for PD-L1-positive EGFR-mutant NSCLC: NJLCG2202. - Kawashima, Y.; Inomata, M.; Saito, R.; Morinaga, D.; Nogawa, H.; Satou, M.; Suzuki, Y.; Yanagisawa, S.; Kikuchi, T.; Jingu, D.; Yoshimura, N.; Harada, T.; et al. (Annals of Oncology, 2024)